Johnson & Johnson (JNJ) 100.96 $JNJ
Intercept Pharmaceuticals' Obeticholic Acid for Liver Diseases Report
M2 - Fri May 23, 2:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfcxg8/intercept) has announced the addition of the "Intercept Pharmaceuticals' Obeticholic Acid for liver diseases" report to their offering. Obeticholic acid (OCA) is a derivative of chenodeoxycholic acid, the dominant component of bile. It is a potent stimulator of farnesoid X receptor and in that way differs both from chenodeoxycholic acid and ursodeoxycholic acid (URSO), another bile acid used therapeutically. Intercept is developing OCA for use in a variety of liver diseases. Primary biliary cirrhosis (PBC), an orphan inflammatory disease of bile ducts, is the lead indication. But non-alcoholic steatohepatitis (NASH), a liver disorder that substantively overlaps with the epidemiology and pathophysiology of the metabolic syndrome is close behind. Intercept has also initiated/reported pilot efforts in bile acid diarrhea (BAD), acute alcoholic hepatitis, and portal hypertension. This initiation report explores these programs in depth, including the underlying rationale for use and a review of the phase II data in the lead PBC and NASH indications. It also explores issues related to the later phase trials for those indications, including the selection of endpoints. In PBC and especially in NASH, the ability to identify those who will have poor long-term outcomes (and thus would benefit from therapy) is difficult. Thus, endpoint selection and FDA's acceptance of data showing impact on those measures becomes a central issue when assessing the probabilities of regulatory success. The report also reviews the rationale and available data from the other programs and also looks at the competitive landscapes for each. Key Topics Covered: 1. Primary biliary cirrhosis (PBC) - The disease - Phase II, including long-term extension data (ICPT 2013 10-K) - POISE - Accelerated Approval in PBC and surrogates of transplant-free survival - Will one study be enough? - In summary 2. Non-alcoholic steatohepatitis (NASH) - NAFLD and NASHa brief review - Phase II study in diabetic NAFLD - The FLINT study - Endpoint issues and approval pathways for NASH - Update on lipid changes in phase II studies of fatty liver 3. Update on other indications 4. Summary opinion - PBC - NASH - Other indications Companies Mentioned - Albireo - Antipodean Pharmaceuticals - Intercept Pharmaceuticals - Johnson & Johnson - Kotobuki Pharmaceuticals - NovImmune - Phenex For more information visit http://www.researchandmarkets.com/research/bfcxg8/intercept About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Dow Inches Higher As Travelers Hits New All-Time High; J&J, Pfizer Also Gain
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 22, 8:05PM CDT
On Thursday, the Dow Jones Industrials gained 10 points, lagging behind the percentage gains in the broader market but still adding to its triple-digit advance from Wednesday. Investors seemed content to ride the ongoing wave of optimism higher,...
Shares of JNJ Up 11.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 22, 5:13PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.62% as of today's recent price of $100.95.
Final Glance: Medical Devices companies
AP - Thu May 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Record World Cup numbers game for FIFA and Brazil
By GRAHAM DUNBAR - AP - Thu May 22, 3:46PM CDT
GENEVA (AP) — The 2014 World Cup is the most valuable, lucrative and expensive in FIFA history.
California counties sue over painkiller marketing
By PAUL ELIAS - AP - Thu May 22, 3:43PM CDT
SAN FRANCISCO (AP) — Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Johnson & Johnson Keeps the Dow's Momentum on Track as Microsoft's Stock Slips
Dan Carroll, The Motley Fool - Motley Fool - Thu May 22, 1:37PM CDT
After a short drop to start the day, stocks have rebounded across the market, with the Dow Jones Industrial Average up 28 as of 2:30 p.m. EDT. The blue-chip index's 30 member stocks are split almost roughly evenly between gainers and losers. ...
Research and Markets: Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qgx5jk/nucynta) has announced the addition of the "Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Midday Glance: Medical Devices companies
AP - Thu May 22, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Thu May 22, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
4 International Cos. Outdo U.S. Counterparts: Total, Sanofi, More
at The Street - Thu May 22, 12:19PM CDT
You can find high-quality, low-volatility, solid, dividend-paying international stocks on your 'home' exchange. Check out the ADR performance for Total, GlaxoSmtihKline, Sanofi and Royal Dutch Shell.
Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
M2 - Thu May 22, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbpdns/nucynta) has announced the addition of the "Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Nucynta ER/Palexia SR (tapentadol) is an opioid analgesic that was developed by Gr?nenthal in conjunction with Johnson & Johnson (J&J), first as an immediate-release formulation indicated for acute pain, and later as an ER formulation for the management of chronic pain. Tapentadol has a dual mechanism of action as an agonist of the ?-opioid receptor and as a norepinephrine reuptake inhibitor, and was developed as an improvement to tramadol, which has weak opioid activity, but also inhibits the reuptake of both serotonin and norepinephrine (Tzschentke et al., 2007). Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Nucynta ER/Palexia SR including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Nucynta ER/Palexia SR for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Nucynta ER/Palexia SR 7 Appendix For more information visit http://www.researchandmarkets.com/research/fbpdns/nucynta
Early Glance: Pharmaceuticals companies
AP - Thu May 22, 9:43AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 22, 9:43AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Why AstraZeneca plc Shareholders Should Be Furious
Cory Renauer, The Motley Fool - Motley Fool - Thu May 22, 8:30AM CDT
It's difficult to overstate the shock I'm feeling over AstraZeneca 's rejection of Pfizer 's generous offer. The floundering company is in the middle of a much needed transformation, but the commercial potential of its pipeline is full of...
Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions
PR Newswire - Thu May 22, 7:45AM CDT
At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets.
National Risperdal Attorneys at The Onder Law Firm Analyze Ongoing Risperdal Lawsuit Progress
PRWeb - Thu May 22, 3:20AM CDT
Attorneys handling national Risperdal lawsuits for The Onder Law Firm report progress in the Risperdal lawsuits filed in Pennsylvania's Complex Litigation Center. According to court documents*, a Motion for Summary Judgment regarding Statute of Limitations was filed earlier this week, on Monday, May 19. This document proposes that persons filing Risperdal lawsuits who took the drug in 2006 or more recently will be considered in this court. A further meeting has been scheduled to discuss the nearly 400 Risperdal lawsuit cases pending under the title Risperdal Litigation, case number 100300296 in the Pennsylvania State Court. According to court documents, the meeting is scheduled to take place on Tuesday, July 15 at 11am. The Philadelphia Complex Litigation Center handles Mass Tort cases and is presided over by the Honorable Arnold L. New.
Johnson & Johnson to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - Thu May 22, 2:23AM CDT
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management conference in Philadelphia, Pa. on October 14-15, 2014. The two-day conference will feature interactive discussions on innovative solutions to resource planning issues.
Dendreon Up on Provenge Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:40PM CDT
Dendreon (DNDN) announced that it presented data from the ProACT and IMPACT studies on Provenge at the AUA
Intercept Pharmaceuticals' Obeticholic Acid for Liver Diseases Report
M2 - Fri May 23, 2:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfcxg8/intercept) has announced the addition of the "Intercept Pharmaceuticals' Obeticholic Acid for liver diseases" report to their offering. Obeticholic acid (OCA) is a derivative of chenodeoxycholic acid, the dominant component of bile. It is a potent stimulator of farnesoid X receptor and in that way differs both from chenodeoxycholic acid and ursodeoxycholic acid (URSO), another bile acid used therapeutically. Intercept is developing OCA for use in a variety of liver diseases. Primary biliary cirrhosis (PBC), an orphan inflammatory disease of bile ducts, is the lead indication. But non-alcoholic steatohepatitis (NASH), a liver disorder that substantively overlaps with the epidemiology and pathophysiology of the metabolic syndrome is close behind. Intercept has also initiated/reported pilot efforts in bile acid diarrhea (BAD), acute alcoholic hepatitis, and portal hypertension. This initiation report explores these programs in depth, including the underlying rationale for use and a review of the phase II data in the lead PBC and NASH indications. It also explores issues related to the later phase trials for those indications, including the selection of endpoints. In PBC and especially in NASH, the ability to identify those who will have poor long-term outcomes (and thus would benefit from therapy) is difficult. Thus, endpoint selection and FDA's acceptance of data showing impact on those measures becomes a central issue when assessing the probabilities of regulatory success. The report also reviews the rationale and available data from the other programs and also looks at the competitive landscapes for each. Key Topics Covered: 1. Primary biliary cirrhosis (PBC) - The disease - Phase II, including long-term extension data (ICPT 2013 10-K) - POISE - Accelerated Approval in PBC and surrogates of transplant-free survival - Will one study be enough? - In summary 2. Non-alcoholic steatohepatitis (NASH) - NAFLD and NASHa brief review - Phase II study in diabetic NAFLD - The FLINT study - Endpoint issues and approval pathways for NASH - Update on lipid changes in phase II studies of fatty liver 3. Update on other indications 4. Summary opinion - PBC - NASH - Other indications Companies Mentioned - Albireo - Antipodean Pharmaceuticals - Intercept Pharmaceuticals - Johnson & Johnson - Kotobuki Pharmaceuticals - NovImmune - Phenex For more information visit http://www.researchandmarkets.com/research/bfcxg8/intercept About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Dow Inches Higher As Travelers Hits New All-Time High; J&J, Pfizer Also Gain
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 22, 8:05PM CDT
On Thursday, the Dow Jones Industrials gained 10 points, lagging behind the percentage gains in the broader market but still adding to its triple-digit advance from Wednesday. Investors seemed content to ride the ongoing wave of optimism higher,...
Shares of JNJ Up 11.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 22, 5:13PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.62% as of today's recent price of $100.95.
Final Glance: Medical Devices companies
AP - Thu May 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Record World Cup numbers game for FIFA and Brazil
By GRAHAM DUNBAR - AP - Thu May 22, 3:46PM CDT
GENEVA (AP) — The 2014 World Cup is the most valuable, lucrative and expensive in FIFA history.
California counties sue over painkiller marketing
By PAUL ELIAS - AP - Thu May 22, 3:43PM CDT
SAN FRANCISCO (AP) — Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Johnson & Johnson Keeps the Dow's Momentum on Track as Microsoft's Stock Slips
Dan Carroll, The Motley Fool - Motley Fool - Thu May 22, 1:37PM CDT
After a short drop to start the day, stocks have rebounded across the market, with the Dow Jones Industrial Average up 28 as of 2:30 p.m. EDT. The blue-chip index's 30 member stocks are split almost roughly evenly between gainers and losers. ...
Research and Markets: Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qgx5jk/nucynta) has announced the addition of the "Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Midday Glance: Medical Devices companies
AP - Thu May 22, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Thu May 22, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
4 International Cos. Outdo U.S. Counterparts: Total, Sanofi, More
at The Street - Thu May 22, 12:19PM CDT
You can find high-quality, low-volatility, solid, dividend-paying international stocks on your 'home' exchange. Check out the ADR performance for Total, GlaxoSmtihKline, Sanofi and Royal Dutch Shell.
Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
M2 - Thu May 22, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbpdns/nucynta) has announced the addition of the "Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Nucynta ER/Palexia SR (tapentadol) is an opioid analgesic that was developed by Gr?nenthal in conjunction with Johnson & Johnson (J&J), first as an immediate-release formulation indicated for acute pain, and later as an ER formulation for the management of chronic pain. Tapentadol has a dual mechanism of action as an agonist of the ?-opioid receptor and as a norepinephrine reuptake inhibitor, and was developed as an improvement to tramadol, which has weak opioid activity, but also inhibits the reuptake of both serotonin and norepinephrine (Tzschentke et al., 2007). Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Nucynta ER/Palexia SR including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Nucynta ER/Palexia SR for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Nucynta ER/Palexia SR 7 Appendix For more information visit http://www.researchandmarkets.com/research/fbpdns/nucynta
Early Glance: Pharmaceuticals companies
AP - Thu May 22, 9:43AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 22, 9:43AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Why AstraZeneca plc Shareholders Should Be Furious
Cory Renauer, The Motley Fool - Motley Fool - Thu May 22, 8:30AM CDT
It's difficult to overstate the shock I'm feeling over AstraZeneca 's rejection of Pfizer 's generous offer. The floundering company is in the middle of a much needed transformation, but the commercial potential of its pipeline is full of...
Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions
PR Newswire - Thu May 22, 7:45AM CDT
At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets.
National Risperdal Attorneys at The Onder Law Firm Analyze Ongoing Risperdal Lawsuit Progress
PRWeb - Thu May 22, 3:20AM CDT
Attorneys handling national Risperdal lawsuits for The Onder Law Firm report progress in the Risperdal lawsuits filed in Pennsylvania's Complex Litigation Center. According to court documents*, a Motion for Summary Judgment regarding Statute of Limitations was filed earlier this week, on Monday, May 19. This document proposes that persons filing Risperdal lawsuits who took the drug in 2006 or more recently will be considered in this court. A further meeting has been scheduled to discuss the nearly 400 Risperdal lawsuit cases pending under the title Risperdal Litigation, case number 100300296 in the Pennsylvania State Court. According to court documents, the meeting is scheduled to take place on Tuesday, July 15 at 11am. The Philadelphia Complex Litigation Center handles Mass Tort cases and is presided over by the Honorable Arnold L. New.
Johnson & Johnson to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - Thu May 22, 2:23AM CDT
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management conference in Philadelphia, Pa. on October 14-15, 2014. The two-day conference will feature interactive discussions on innovative solutions to resource planning issues.
Dendreon Up on Provenge Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:40PM CDT
Dendreon (DNDN) announced that it presented data from the ProACT and IMPACT studies on Provenge at the AUA
